Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03027960 · ClinicalTrials.gov registry record · Phase 1
Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03027960 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 21 participants.
The verdict
NCT03027960, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The investigators propose a small pilot proof of concept study to not only prove the existence of, but also probe the mechanisms underlying cardio-renal effects of empagliflozin in patients with heart failure. The investigators propose a 50 patient randomized, double-blind, placebo-controlled crossover study with patients with stable HF, type II diabetes and an eGFR \>45ml/min/1.73 m2 who are chronically receiving loop diuretics.
Interventions
- DRUG Empagliflozin
- DRUG Placebo Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2019-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03027960
The ClinicalTrials.gov registry entry for NCT03027960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Empagliflozin is the first listed.
NCT03027960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03027960 about?
NCT03027960 is a clinical study titled "Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects". The investigators propose a small pilot proof of concept study to not only prove the existence of, but also probe the mechanisms underlying cardio-renal effects of empagliflozin in patients with heart failure. The investigators propose a 50 patient randomized, double-blind, placebo-controlled crosso...
What is the current status of trial NCT03027960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-06-27. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT03027960?
The interventions under investigation include: Empagliflozin (DRUG), Placebo Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT03027960?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.